
Oil tycoon Wilmer Ruperti showed up for a meeting with Venezuela’s intelligence agency last Thursday. A week later, he’s still in custody, one of his lawyers told Semafor.
“We’ve reached out to everybody trying to get proof of life or some support,” Winston & Strawn’s Cari Stinebower said, adding that officials still haven’t conveyed “how he’s being treated or why he’s being detained.”
Ruperti, who arrived at the meeting with a security detail, is a Venezuelan Italian shipping magnate who trades in petroleum coke. His detainment followed interim President Delcy Rodríguez’s decision to elevate the agency’s longtime chief to defense minister.
“The message is that Venezuela is open for business — but detaining businessmen for days on end without any due process or access to counsel is more old regime,” Stinebower said. “This is not law and order and not conducive of a welcoming business environment.”
The State Department and Energy Department did not respond to requests for comment.
LATEST POSTS
- 1
The Force of Positive Reasoning: Day to day Attestations - 2
How we came to be: Scientists get first look at the evolution of early complex animals - 3
Figure out How to Recognize the Right Areas for 5G Pinnacles\ - 4
Tech for Wellbeing: Applications and Devices for a Better You - 5
Help Your Efficiency: 10 Authoritative Apparatuses to Attempt
Flourishing in a Remote Workplace: Individual Techniques
James Webb Space Telescope finds strongest evidence yet for atmosphere around rocky exoplanet: 'It's really like a wet lava ball'
NASA Artemis II tracker: Crew less than 60,000 miles from moon ahead of Monday flyby
Instructions to Keep up with Your Traded Teeth for Life span
Swap The Amalfi Coast For This Low-Cost Ligurian Seaside Town
From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
6 Natural products High In Vitamins,Which One Do You Like to Eat
Amid growing bipartisan scrutiny of Pete Hegseth, Trump says he 'wouldn't have wanted … a second strike' on alleged Venezuelan drug boat survivors
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug













